End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.64 USD | -1.52% |
|
-4.48% | +18.82% |
06-18 | Alvotech, Advanz Pharma Collaborate to Supply, Commercialize Proposed Biosimilar to Eylea in Europe | MT |
06-18 | Alvotech Enters Commercialization Deal for Eylea Biosimilars with Advanz Pharma | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.82% | 3.78B | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+35.88% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- ALVO Stock
- News Alvotech
- Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar